Literature DB >> 21742560

Pathology of mixed Müllerian tumours.

Emanuela D'Angelo1, Jaime Prat.   

Abstract

The term 'mixed Müllerian tumour' applies to uterine tumours composed of epithelial and mesenchymal elements of Müllerian origin. These neoplasms are classified into adenomyomas, adenofibromas, adenosarcomas, and carcinosarcomas (malignant Müllerian mixed tumours) based on whether the epithelial and stromal elements are benign or malignant. The rare atypical polypoid adenomyoma usually involves the lower uterine segment and, on curettings, may be confused with invasive adenocarcinoma. Adenosarcomas are low-grade neoplasms classified halfway along the spectrum of mixed Müllerian tumours, with adenofibromas at one end and carcinosarcomas (malignant Müllerian mixed tumours) at the other. Some tumours currently classified as 'adenofibromas' on the basis of their low mitotic count and lack of nuclear atypia are, in fact, well differentiated adenosarcomas. Carcinosarcoma is composed of admixed but distinctive carcinomatous and sarcomatous elements. On the basis of the clonal origin of both tumour components, carcinosarcomas are currently thought to be metaplastic carcinomas rather than uterine sarcomas.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21742560     DOI: 10.1016/j.bpobgyn.2011.05.010

Source DB:  PubMed          Journal:  Best Pract Res Clin Obstet Gynaecol        ISSN: 1521-6934            Impact factor:   5.237


  16 in total

1.  T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2.

Authors:  Roberta Nicoletti; Salvatore Lopez; Stefania Bellone; Emiliano Cocco; Carlton L Schwab; Jonathan D Black; Floriana Centritto; Liancheng Zhu; Elena Bonazzoli; Natalia Buza; Pei Hui; Delia Mezzanzanica; Silvana Canevari; Peter E Schwartz; Thomas J Rutherford; Alessandro D Santin
Journal:  Clin Exp Metastasis       Date:  2014-11-15       Impact factor: 5.150

2.  Identical TP53 mutations in pelvic carcinosarcomas and associated serous tubal intraepithelial carcinomas provide evidence of their clonal relationship.

Authors:  Laura Ardighieri; Luigi Mori; Sara Conzadori; Mattia Bugatti; Marcella Falchetti; Carla Maria Donzelli; Antonella Ravaggi; Franco E Odicino; Fabio Facchetti
Journal:  Virchows Arch       Date:  2016-04-08       Impact factor: 4.064

3.  Impact of adjuvant therapy on recurrence patterns in stage I uterine carcinosarcoma.

Authors:  Koji Matsuo; Kohei Omatsu; Malcolm S Ross; Marian S Johnson; Mayu Yunokawa; Merieme M Klobocista; Dwight D Im; Stephen H Bush; Yutaka Ueda; Tadao Takano; Erin A Blake; Kosei Hasegawa; Tsukasa Baba; Masako Shida; Shinya Satoh; Takuhei Yokoyama; Hiroko Machida; Sosuke Adachi; Yuji Ikeda; Keita Iwasaki; Takahito M Miyake; Shiori Yanai; Masato Nishimura; Tadayoshi Nagano; Munetaka Takekuma; Satoshi Takeuchi; Tanja Pejovic; Mian Mk Shahzad; Frederick R Ueland; Joseph L Kelley; Lynda D Roman
Journal:  Gynecol Oncol       Date:  2017-02-16       Impact factor: 5.482

4.  A predictive diagnostic model using multiparametric MRI for differentiating uterine carcinosarcoma from carcinoma of the uterine corpus.

Authors:  Yuki Kamishima; Mitsuru Takeuchi; Tatsuya Kawai; Takatsune Kawaguchi; Ken Yamaguchi; Naoki Takahashi; Masato Ito; Toshinao Arakawa; Akiko Yamamoto; Kazushi Suzuki; Masaki Ogawa; Moe Takeuchi; Yuta Shibamoto
Journal:  Jpn J Radiol       Date:  2017-06-05       Impact factor: 2.374

Review 5.  Epithelial to mesenchymal transition in the pathogenesis of uterine malignant mixed Müllerian tumours: the role of ubiquitin proteasome system and therapeutic opportunities.

Authors:  I A Voutsadakis
Journal:  Clin Transl Oncol       Date:  2012-04       Impact factor: 3.405

6.  Use of mutation profiles to refine the classification of endometrial carcinomas.

Authors:  Melissa K McConechy; Jiarui Ding; Maggie Cu Cheang; Kimberly Wiegand; Janine Senz; Alicia Tone; Winnie Yang; Leah Prentice; Kane Tse; Thomas Zeng; Helen McDonald; Amy P Schmidt; David G Mutch; Jessica N McAlpine; Martin Hirst; Sohrab P Shah; Cheng-Han Lee; Paul J Goodfellow; C Blake Gilks; David G Huntsman
Journal:  J Pathol       Date:  2012-07-18       Impact factor: 7.996

7.  Multiple pulmonary metastases with halo-sign from malignant mixed Müllerian tumors.

Authors:  Hong-Wei Tian; Wei-Bing Yang; Meng-Jie Yang; Jing-Yuan Liu; Jian-Chu Zhang; Xiao-Nan Tao; Qiong Zhou
Journal:  Oncol Lett       Date:  2017-09-22       Impact factor: 2.967

8.  Ovarian adenosarcoma simulating a simple cyst in a young patient.

Authors:  Leonardo Gomes da Fonseca; Aloísio Felipe-Silva; Samanta Cabral Severino da Silva; Paulo Francisco Ramos Margarido; Elias Abdo; Paulo Marcelo Gehm Hoff
Journal:  Autops Case Rep       Date:  2014-06-30

Review 9.  Target Therapies for Uterine Carcinosarcomas: Current Evidence and Future Perspectives.

Authors:  Salvatore Giovanni Vitale; Antonio Simone Laganà; Stella Capriglione; Roberto Angioli; Valentina Lucia La Rosa; Salvatore Lopez; Gaetano Valenti; Fabrizio Sapia; Giuseppe Sarpietro; Salvatore Butticè; Carmelo Tuscano; Daniele Fanale; Alessandro Tropea; Diego Rossetti
Journal:  Int J Mol Sci       Date:  2017-05-20       Impact factor: 5.923

10.  Malignant mixed Mullerian tumour of the uterus.

Authors:  S K Rajshekar; B Guruprasad; Pn Shakunthala; Praveen Rathod; Uma Devi; Ud Bafna
Journal:  Ecancermedicalscience       Date:  2013-04-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.